Citadel Advisors’s Marker Therapeutics MRKR Stock Holding History

Citadel Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,120	Closed	-$5K	–	13654
2022 Q1	$5K	Sell	1,120 -1,200	-52%	-$6.86K	﹤0.01%	13425
2021 Q4	$22K	Sell	2,320 -150	-6%	-$1.99K	﹤0.01%	13562
2021 Q3	$42K	Sell	2,470 -2,280	-48%	-$46.7K	﹤0.01%	13456
2021 Q2	$133K	Sell	4,750 -16,980	-78%	-$447K	﹤0.01%	12639
2021 Q1	$487K	Buy	+21,730	New	+$497K	﹤0.01%	9733
2020 Q3	–	Sell	-1,040	Closed	-$22K	–	10488
2020 Q2	$22K	Buy	+1,040	New	+$22.7K	﹤0.01%	9534
2019 Q4	–	Sell	-1,930	Closed	-$99K	–	9505
2019 Q3	$99K	Buy	1,930 +660	+52%	+$39K	﹤0.01%	8485
2019 Q2	$101K	Buy	+1,270	New	+$75.4K	﹤0.01%	8527

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Citadel Advisors's MRKR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Marker Therapeutics (MRKR) in Q2 2026: 32,517 shares worth $47.8K. The stake represents ﹤0.01% of the portfolio and ranks #13135 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in MRKR as recently as Q4 2025.

Citadel Advisors first reported a position in MRKR in Q3 2019 and has held it in 13 quarters since. The position peaked at $817K in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

Citadel Advisors held 32,517 shares of Marker Therapeutics worth $47.8K as of Q2 2026.
Marker Therapeutics was a new Citadel Advisors position in Q2 2026.
Marker Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13135 holding.
Citadel Advisors first reported a position in Marker Therapeutics in Q3 2019 and has held it in 13 quarters since.
Citadel Advisors's Marker Therapeutics position peaked at $817K in Q2 2021.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.